Adjuvant Treatment of Digestive Tract Tumors
ConditionAdjuvant Treatment
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorXijing Hospital
About this trial
To evaluate the 3-year Disease-free survival rate(DFSR) of patients with locally advanced gastric cancer and colorectal cancer treated with anlotinib combined with adjuvant chemotherapy.
Eligibility criteria
Qualifiers
1.18 years old ≤ age ≤ 75 years old, male or female;
2. ECOG score 0~2 points;
3. Patients with locally advanced gastric cancer and colorectal cancer after radical surgery (R0 resection);
4. Gastric cancer: patients with stage III (pT1N3bM0, pT2N3M0, pT3N2-3M0, pT4aN1-3M0, pT4bN0-3M0);
Disqualifiers
1. Postoperative distal metastasis or failure to achieve R0 resection;
2. Have experienced any anti-tumor treatment before surgery, including chemotherapy, radiotherapy and targeted drug treatment;
3. Patients with contraindications to chemotherapy;
4. Other malignant tumors in the past 3 years;
Trial design
Treatments tested in this trial
- anlotinib+CAPEOX/SOX
Treatment groups
100 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov